Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-12-08 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于贝达药业股份有限公司申请向特定对象发行股票的审核问询函
Capital/Financing Update Classification · 95% confidence The document is an official inquiry letter from a securities exchange regarding a company's application to issue shares to specific investors. It references regulatory rules about securities issuance, discusses details about the share issuance plan, funding usage, risks, and requests clarifications and confirmations from the company and its advisors. The document is not a financial report, earnings release, or presentation, but rather a regulatory inquiry related to a capital raising activity. It is not a report publication announcement since it contains substantive content and questions. Therefore, the document fits best under 'Capital/Financing Update' (CAP), as it concerns the review and approval process of a specific share issuance to particular investors.
2022-12-08 Chinese
关于收到深圳证券交易所《关于贝达药业股份有限公司申请向特定对象发行股票的审核问询函》的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Betta Pharmaceuticals Co., Ltd. regarding the receipt of an inquiry letter from the Shenzhen Stock Exchange about the company's application for a private placement of shares. It discusses the review process, the need for approval from the China Securities Regulatory Commission, and the company's commitment to disclose further information as required. The document is short (666 characters) and serves as a regulatory update about a financing activity, specifically a private placement of shares. It does not contain financial statements or detailed financial data, nor is it a full report or presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-12-08 Chinese
关于归还用于暂时补充流动资金的闲置募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the return of idle raised funds temporarily used to supplement working capital. It references prior board meetings and compliance with regulatory guidelines on the use of raised funds. The document is short (792 characters) and serves as a formal notification of a capital management action rather than a detailed financial report or audit. It does not contain financial statements or detailed analysis but is an update on capital usage and compliance. Therefore, it fits best under Capital/Financing Update (CAP).
2022-12-07 Chinese
浙江天册律师事务所关于贝达药业股份有限公司2022年度向特定对象发行A股股票的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by Zhejiang Tiance Law Firm regarding a 2022 private placement (non-public issuance) of A shares by Betta Pharmaceuticals Co., Ltd. It extensively covers the legal qualifications, approvals, authorizations, and compliance with relevant laws and regulations for the issuance. The document includes detailed sections on the issuance approval, issuer qualifications, substantive conditions for issuance, and legal compliance. It is not a financial report, earnings release, or management discussion but a legal opinion related to a capital raising event. This fits the category of Capital/Financing Update (CAP), as it pertains to a specific financing activity (private placement of shares) and includes legal opinions on the issuance process and compliance. The document length (15,000 characters) and content confirm it is the actual legal opinion report, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2022-12-01 Chinese
关于2022年度向特定对象发行A股股票申请获得深圳证券交易所受理的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (527 characters) regarding the acceptance by the Shenzhen Stock Exchange of the company's application for a specific issuance of A shares. It mentions the regulatory review process and the need for approval by the China Securities Regulatory Commission. There is no detailed financial data or report content, only a notification of the acceptance of the application and next steps. This fits the category of a Capital/Financing Update (CAP) as it relates to fundraising activities and capital structure changes.
2022-12-01 Chinese
公司最近一年的财务报告及其审计报告以及最近一期的财务报告
Audit Report / Information Classification · 95% confidence The document is titled as an "审计报告及财务报表" which translates to "Audit Report and Financial Statements" for the fiscal year 2021. It includes detailed audit opinions, key audit matters, and extensive financial statements such as consolidated and parent company balance sheets, profit and loss statements, and cash flow statements. The presence of an auditor's opinion, audit basis, and detailed financial data confirms this is a full audit report with financial statements. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR). FY 2021
2022-12-01 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.